June 28, 2019 Portfolio News from ARCH Venture Partners | Share Karuna Makes Nasdaq Debut with $89M IPO
June 26, 2019 Portfolio News from ARCH Venture Partners | Share After Raising $158M, This Upstart’s Founders Have Star Backers and Plans to Break New Ground in Gene Therapy
June 14, 2019 Portfolio News from ARCH Venture Partners | Share BlackThorn Therapeutics Closes $76 Million Series B to Advance Targeted Therapeutics for Mental Health
May 23, 2019 Portfolio News from ARCH Venture Partners | Share Locana Launches with $55M for RNA-Targeting Gene Therapies
March 18, 2019 Portfolio News from ARCH Venture Partners | Share Karuna Announces $68 Million Series B Financing
March 12, 2019 ARCH News from ARCH Venture Partners | Share ARCH Receives NVCA Firm Of The Year Award
March 6, 2019 Portfolio News from ARCH Venture Partners | Share Gene editing startup Beam Therapeutics raises $135M Series B round
March 5, 2019 Portfolio News from ARCH Venture Partners | Share Erasca™- AI Oncology Startup Announces Series A Extension
March 1, 2019 Portfolio News from ARCH Venture Partners | Share Maze Therapeutics Launches to Focus on Translating Genetic Insights into New Medicines
February 7, 2019 Portfolio News from ARCH Venture Partners | Share New York Biotech Raises $61 Million To Keep Cancer Cells Dormant, Bucking Conventional Treatments
February 7, 2019 Portfolio News from ARCH Venture Partners | Share Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic
January 4, 2019 Portfolio News from ARCH Venture Partners | Share Sana Biotechnology Launches Focusing on Engineering Cells to Create a New Class of Medicines
